Sign in Subscribe
COVID-19

COVID-19 Vaccine Efficacy in Children with Previous Multisystem Inflammatory Syndrome (MIS-C)

Strategic Insights

— 1 min read

Children with a history of multisystem inflammatory syndrome (MIS-C) can develop a robust immune response to SARS-CoV-2 vaccination, according to new research. The findings suggest that vaccination is effective at boosting SARS-CoV-2-specific immune responses in a small group of children with previous MIS-C. The study compared immune responses to SARS-CoV-2 vaccination in children over the age of 12 years with previous MIS-C and healthy children. The research demonstrated that vaccination does not induce inflammatory cytokine or gene expression responses resembling acute MIS-C.

Key Takeaways:

  • The study assessed immune responses to SARS-CoV-2 vaccination in children over the age of 12 years with previous MIS-C and compared them to healthy children.
  • The research demonstrated that vaccination is effective at boosting SARS-CoV-2-specific immune responses in a small group of children with previous MIS-C.
  • The study found that the immune responses to SARS-CoV-2 vaccination were similar between children with a history of MIS-C and healthy children.
  • A transient increase in SARS-CoV-2-specific CD4 T cells expressing TCR Vb21.3, a non-specific T cell subset previously found to be enriched in patients with MIS-C, was demonstrated in two of the children with previous MIS-C.
  • The research concluded that although larger-scale studies are needed to confirm these findings, the present evidence supports SARS-CoV-2 vaccination in children with previous MIS-C.
  • The study involved nine participants, including three children with previous MIS-C and four healthy children who received two doses of the BNT162b2 vaccine.
  • Blood was collected before the first dose, one week after the first dose, one week after the second dose, and three weeks after the second dose to assess immune responses.

Statistics:

  • 3 children with previous MIS-C and 4 healthy children participated in the study.
  • 2 doses of the BNT162b2 vaccine were administered to all participants.
  • Blood samples were collected at 4 time points to assess immune responses: before the first dose, 1 week after the first dose, 1 week after the second dose, and 3 weeks after the second dose.
  • The study demonstrated that vaccination does not induce inflammatory cytokine or gene expression responses resembling acute MIS-C in either group.

Sources:

  • Humanal, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C. Vaccine, 2025; 62, 127461.

Read more